| INTRODUCTION
Colorectal cancer (CRC) is the most prevalent cancer of the gastrointestinal tract worldwide. The incidence of CRC has increased over the past several decades because of western dietary habits and systematized healthcare program based on endoscopy in South Korea. There are various CA or CRC screening tests, and they include fecal-occult blood testing (FOBT) or exfoliated DNA, double-contrast barium enema (DCBE), endoscopic assessment such as flexible colonofibroscopy (CFS), computed tomographic colonography (CTC), and multiple tumor markers (MTM) including carcinoembryonic antigen (CEA), cancer antigen 19-9 (CA19-9), and cytokeratin-19 soluble in serum fragment (CYFRA 21-1). [3] [4] [5] The usual screening assessment of CRC mainly consists of a few different methods, and among them, FOBT with CFS combination including MTM is usually applied to the healthcare program in South Korea. Because DCBE is less effective, its preparation is more complicated than the other methods and its application gives a radiation burden to the patients, it is seldom used.
Although CFS has a distinctive advantage of simultaneously examining and managing treatment of diverse polyp lesions including CA, in the patients aged under 50 years in Western countries, it should not be generally recommended because it may have an intricate preparation process, with inaccurate results, and perforation or bleeding during the procedure. Although CTC offers the possibility of replacing endoscopic procedure, the possibility of unnecessary irradiation should not be overlooked especially in younger people and its result is not always satisfactory.
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The MTM approach provides a simple analytical tool not only to diagnose CRC but also to be used for a broaden population checking program. 4, 5 In CRC, CEA is the most important marker to evaluate staging before treatment and to detect disease recurrence. 7 However, because of poor sensitivity and specificity in managing early stage CRC, CEA cannot be routinely recommended for screening. 8 Although CA19-9 is known to play a role in evaluating disease recurrence and predicting prognosis of patients with advanced stage CRC, its role as a screening test has not been systematically investigated.
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Cytokeratin-19 soluble in serum fragment is known as one of the cytokeratin tumor markers, like tissue polypeptide antigen (TPA) and tissue polypeptide specific antigen (TPS). 11, 12 To the best of our knowledge, there are few reports investigating the clinical utility with respect to CRC or CA screening with these MTM. Other factors like thyroid-stimulating hormone (TSH), high-sensitivity C-reactive protein (hsCRP), cholesterol levels (triglyceride (TG), high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C)) have been reported as being possibly associated with CA or CRC development and they were included in this study.
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The aim of this study was to evaluate the diagnostic importance of the abovementioned diverse biologic markers and especially of CYFRA 21-1 to early diagnose a benign colon polyp (BCP) or CA and the possibility to be used as a screening tool.
| MATERIALS AND METHODS

| Patients
A total of 778 subjects aged over 45 years who underwent an annual healthcare program and screening colonoscopy at our health screening center, between 2012 and 2015 were enrolled in this study.
For this study, we received approval from the Institutional Review Measurements of TSH (Cisbio Assays, Codolet, France) were performed by the same method.
| Enzyme immunoassay for CEA, AFP, hsCRP, TG, LDL-C, and HDL-C
Blood samples were collected to determine the serum level for AFP, CEA, LDL-C, HDL-C, TG, and hs-CRP assay. Measurements of AFP and CEA were performed on the fully automated Roche system using the cobas e platform (Roche Diagnostics, Penzberg, Germany). hs-CRP, HDL-C, and LDL-C levels in each sample were also measured on the fully automated Roche system using the cobas c platform (Roche Diagnostics). All of these automated assays took 18 minutes for detection of each analyte, and they were analyzed according to the manufacturer's method sheets. The test principle for CEA and AFP was the sandwich principle, i.e., the electrochemiluminescence immunoassay for use on cobas e immunoassay analyzers. The principle of homogeneous enzymatic colorimetric test was used for LDL-C and HDL-C, which has been described elsewhere.
19,20 TG was tested by using the enzymatic colorimetric method 21 and hs-CRP was assessed by the particle enhanced immunoturbidimetric method, in which human CRP agglutinates with latex particles coated with monoclonal anti-CRP antibodies. The precipitate was determined turbidimetrically 22, 23 on cobas c analyzers.
| Statistics
Total estimated data were expressed as mean±SD, and P values of Evaluation of the significant relationship among the three groups (benign controls, patients with only BCP, and patients with CA) was performed by one-way ANOVA with Bonferroni's and Dunnett's three multiple comparison tests.
| RESULTS
| Patient characteristics
Overall characteristics of the enrolled patients and control groups are shown in Table 1 . There were a higher number of men than women among the total enrolled subjects and patients with CA (P<.001). In patients with BCP and patients with CA, the presence of BCP and CA was dominant in the rectosigmoid colon (P<.001) ( Table 1 ). But in case of BCP, the distribution in the sigmoid colon and the rectum was more or less different (149 vs 108), while in case of adenomas, the number of sites of sigmoid CA was higher than the number of sites of rectal CA (136 vs 32), and this result was noted in patients with ACA (33 vs 8).
| Correlational relationship between multiple tumor markers and biochemical parameters in patients with colon adenoma
According to Figure 1C ). In all analytical cases including differentiation between negative or benign controls and patients with total colon polyps, CA and ACA, the ROC analysis suggested that CYFRA 21-1 was superior to the other tumor markers (Figures 1 and 2) . Sensitivity of CYFRA 21-1 for CA and ACA with adjusted cutoff values estimated from the ROC analysis was 22.3% and 30.5%, respectively (cutoff value: 1.02 and 1.03 ng/mL).
Sensitivity of CYFRA 21-1 was significantly higher than that of the other parameters (Table 4) .
| ANOVA with post hoc tests among benign controls, patients with a benign colon polyp, and patients with colon adenoma
To evaluate the relationship between benign controls, patients with BCP, and patients with CA, ANOVA with post hoc tests was performed (Table 5 ). In our analysis, benign controls were younger than patients with a CA. Subjects with colon adenoma had a higher hsCRP level than benign controls and patients with only BCP. With respect to CEA, benign controls showed a significantly lower value than patients with CA. CYFRA 21-1 alone showed significant stepwise comparative potential among the three groups (P<.001). There was no significant comparative result between benign controls and patients with BCP or CA in the other tumor markers and biochemical factors. T A B L E 3 Analysis of Receiver operating Characteristic (ROC) curves between negative controls and patients with advanced colon adenoma and between benign controls and patients with advanced colon adenoma
T A B L E 2 Correlative relationship between MTM and biochemical parameters in patients with colon adenoma
| DISCUSSION
In the current study, the efficacy of MTM in differentiating between the benign control group and patients with CA or ACA was evaluated.
The important finding of our study suggests that CYFRA 21-1 has a more significant discriminative ability than the other biological markers with respect to screening population over the age of 45 years with no past medical history. In addition, CYFRA 21-1 showed significantly different sequential values from benign controls to patients with ACA. Cytokeratin is one of the structural proteins found in the intracytoplasmic cytoskeleton of epithelial tissue. 24 Until now, twenty different cytokeratin members have been discovered. Because cytokeratin plays a role in maintaining normal cell environment as a filamentous structure, it is released following cell death and its soluble fragment can be detected in the serum. 25 Hence, CYFRA 21-1 assay is used to specifically detect the soluble fragment of cytokeratin 19 in blood specimens with two monoclonal antibodies. In the field of CRC, among multiple serum tumor markers, CEA has been generally utilized for monitoring after neoadjuvant or palliative diverse medical treatment, post operative follow-up after curative surgery, and detection of recurrence. 7, 33, 34 But, when it comes to screening of CRC or CA, its efficacy has not been proved, and rather, it is controversial. 35 On the other hand, according to the results of this study, CYFRA 21-1 could become one of the potential screening tools to evaluate ACA regarded as premalignant lesion possibly progressing to colon cancer in asymptomatic individuals. In addition, CYFRA 21-1 has been found to be less affected by age, sex, smoking, and pregnancy, 36 and its elevated level is less often detected in benign liver diseases and renal failure; hence, high specificity of CYFRA 21-1 has been reported for NSCLC.
37,38
Inflammation has been known to be attributed to the process of development of CA or adenocarcinoma. 15 Hence, hsCRP quantifying the degree of inflammation, albeit non-specific, was evaluated as one of the clinical parameters in our study. As we had predicted, hsCRP showed a relatively considerable calibration ability to evaluate patients with colon polyps or adenoma among the enrolled subjects, although its ability was lower than that of CYFRA 21-1, based on the ROC analysis. Of course, the application of hsCRP alone in a screening program for CRC is not enough, but a new approach combined with serum tumor markers or FOBT could be useful for estimating its unique efficacy as a screening tool. Although CFS has been recognized T A B L E 5 Comparitive relationship of multiple tumor markers and biochemical parameters between benign controls, patients with only benign colon polyps and patients with colon adenomas included. Because of the criteria of a single center study and age requirement (more than 45 years), the sample size in our study was not large, but because healthcare programs are different at each medical center, a large-scale multicenter study that includes our MTM combination including CYFRA 21-1 is difficult but it is warranted to evaluate the comparison of MTM in detecting not only CA but also other premalignant conditions.
| CONCLUSION
Our study demonstrates that CYFRA 21-1 showed significant diagnostic performance in differentiating patients with CA from asymptomatic adults aged over 45 years, compared to the multiple investigated biomarkers. In addition, hsCRP might offer the possibility of being useful as a supportive screening tool in the diagnosis of colorectal neoplasm. Large-scale researches are required to establish the clinical utility of CYFRA 21-1 in CA detection or screening of malignancies including CRC.
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